VIRTICI LLC — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): The goal of this project is to extend the developmen
VIRTICI LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $417,336
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-088
- NAICS
- —
- Place of performance
- WA
- Period
- —
Description
DESCRIPTION (provided by applicant): The goal of this project is to extend the development of a novel compound that can reprogram memory T lymphocytes to induce tolerance in allergic rhinitis (AR). AR is one of the most common chronic diseases in the United States (US) and is estimated to affect more than 50 million people [1,2]. As a result, the annual US economic burden of AR exceeds 12 billion, with half of these costs attributed to prescription medications [3]. Globally, over 400 million people sufferfrom AR, with an estimated economic burden of greater than 20B [4] and the prevalence continues to increase. Allergic rhinitis is a chronic inflammatory disease of the upper airway. It occurs when an allergen, such as dander, dust, or pollen is inhaled by an individual with a sensitized immune system. The allergic inflammation can result in nasal congestion, headaches, hoarseness, postnasal drip, tonsillitis, sore throat, sneezing and stuffy nose. Due to recurring inflammation o the sinuses, AR p